DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
McDonald's - 1 Gilead - 1 Daniel O'Day - 1 lenacapavir - 1 Michael Yee - 1 Yee - 1
Top related locs:
Colorado and Nebraska Colorado Gilead
Top related orgs:
Centers for Disease Control - 2 Prevention - 1 CDC - 1 U.S . Food - 1 Drug Administration - 1 PrEP - 1 Jefferies - 1 CNBC - 1

Search resuls for: "Annika Kim Constantino Jacob Pramuk"


2 mentions found


☆ McDonald's shares fall after CDC says E. coli outbreak linked to Quarter Pounders
  + stars: | 2024-10-22 | by ( Annika Kim Constantino Jacob Pramuk | Annika Kim Constantino | Jacob Pramuk | ) www.cnbc.com   time to read: +1 min
McDonald's shares dropped in premarket trading Wednesday morning after the Centers for Disease Control and Prevention said an E. coli outbreak linked to McDonald's Quarter Pounder burgers has led to 10 hospitalizations and one death. "Most" sick people reported eating a McDonald's Quarter Pounder, the CDC added. McDonald's shares dropped about 7% in trading before the market opened Wednesday. In a statement Tuesday, McDonald's said it is taking "swift and decisive action" following the E. Coli outbreak in certain states. McDonald's has instructed all local restaurants to remove slivered onions from their supply and has paused the distribution of that ingredient in the affected area.
Persons: McDonald's Organizations: Centers for Disease Control, Prevention, CDC Locations: Colorado and Nebraska, Colorado
☆ Gilead's twice-yearly shot cut HIV infections by 96% in trial
  + stars: | 2024-09-12 | by ( Annika Kim Constantino Jacob Pramuk | Annika Kim Constantino | Jacob Pramuk | ) www.cnbc.com   time to read: +2 min
Gilead 's twice-yearly shot reduced HIV infections by 96% in a second large study, the company said Thursday. The positive phase three trial data on lenacapavir sets the stage for likely approval by the U.S. Food and Drug Administration for HIV prevention. The company said 99.9% of participants who received lenacapavir did not acquire HIV, with two cases among 2,180 people. Gilead in June also said lenacapavir was 100% effective at preventing HIV in another late-stage trial with cisgender women. The trial results should lead to an FDA approval and launch in the market by 2025, Yee said.
Persons: Gilead, Daniel O'Day, lenacapavir, Michael Yee, Yee Organizations: U.S . Food, Drug Administration, PrEP, Centers for Disease Control, Jefferies, CNBC, YouTube Locations: Gilead
0 next >>
Total: 2